Non-Small Cell Lung Cancer
Aegera Therapeutics Initiates a Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Published in Respiratory Therapeutics Week, January 19th, 2009
The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
More Articles from Respiratory Therapeutics Week
- University of California - San Diego
Lung cancer cells activate inflammation to induce metastasis - Allergies
New allergies data have been reported by J. Bilsborough and co-authors - Allergies
New allergies study findings have been reported by scientists at National Institutes of Health - Asthma
American Asthma Foundation Announces Breakthrough Discovery - Asthma
New asthma findings from B.L. Jones and co-authors described - Asthma
Studies from Medical University of Graz have provided new information about asthma - More from this issue of Respiratory Therapeutics Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
